66 results
8-K
EX-10.1
CRSP
CRISPR Therapeutics AG
23 May 24
Departure of Directors or Certain Officers
8:14am
be determined by Parent in its sole discretion.
(d)Expenses. During the Employment Period, the Executive shall be entitled to receive reimbursement for all … benefits provided and expenses eligible for reimbursement under this Agreement shall be provided by the Company or incurred by the Executive during the time
8-K
EX-99.1
CRSP
CRISPR Therapeutics AG
8 May 24
CRISPR Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results
4:15pm
; adequate pricing or reimbursement may not be secured to support continued development or commercialization of exa-cel following regulatory approval
8-K
EX-99.1
2koh72
21 Feb 24
CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
7:45am
8-K
EX-99.1
1kjcjw
6 Nov 23
CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2023 Financial Results
4:33pm
8-K
EX-10.1
aj4ksro5
14 Oct 21
CRISPR Therapeutics Announces Transition of Chief Financial Officer
7:15am
S-3ASR
n60f 755asb4pxig2
29 Jul 21
Automatic shelf registration
5:17pm
S-3ASR
EX-4.2
dpc5p9nlubr cjt
29 Jul 21
Automatic shelf registration
5:17pm
S-3ASR
EX-4.1
2y1e95zv hz39ig5gc
29 Jul 21
Automatic shelf registration
5:17pm